-
Something wrong with this record ?
IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives
H. Malcova, Z. Strizova, T. Milota, I. Striz, A. Sediva, D. Cebecauerova, R. Horvath
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- MeSH
- Anti-Inflammatory Agents therapeutic use MeSH
- Hereditary Autoinflammatory Diseases drug therapy immunology MeSH
- Interleukin-1 antagonists & inhibitors MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Autoinflammatory diseases (AIDs) represent a rare and heterogeneous group of disorders characterized by recurrent episodes of inflammation and a broad range of clinical manifestations. The most common symptoms involve recurrent fevers, musculoskeletal symptoms, and serositis; however, AIDs can also lead to life-threatening complications, such as macrophage activation syndrome (MAS) and systemic AA amyloidosis. Typical monogenic periodic fever syndromes include cryopyrin-associated periodic fever syndrome (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency/hyper IgD syndrome (MKD/HIDS), and familial Mediterranean fever (FMF). However, a number of other clinical entities, such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease (AOSD), Kawasaki disease (KD) and idiopathic recurrent pericarditis (IRP), display similar phenotypical and immunological features to AIDs. All these diseases are pathophysiologicaly characterized by dysregulation of the innate immune system and the central pathogenic role is attributed to the IL-1 cytokine family (IL-1α, IL-1β, IL-1Ra, IL-18, IL-36Ra, IL-36α, IL-37, IL-36β, IL-36g, IL-38, and IL-33). Therefore, reasonable therapeutic approaches aim to inhibit these cytokines and their pathways. To date, several anti-IL-1 therapies have evolved. Each drug differs in structure, mechanism of action, efficacy for the treatment of selected diseases, and side effects. Most of the available data regarding the efficacy and safety of IL-1 inhibitors are related to anakinra, canakinumab, and rilonacept. Other promising therapeutics, such as gevokizumab, tadekinig alfa, and tranilast are currently undergoing clinical trials. In this review, we provide sophisticated and up-to-date insight into the therapeutic uses of different IL-1 inhibitors in monogenic periodic fever syndromes.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019325
- 003
- CZ-PrNML
- 005
- 20220425111549.0
- 007
- ta
- 008
- 210728s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fimmu.2020.619257 $2 doi
- 035 __
- $a (PubMed)33603750
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Malcova, Hana $u Department of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia
- 245 10
- $a IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives / $c H. Malcova, Z. Strizova, T. Milota, I. Striz, A. Sediva, D. Cebecauerova, R. Horvath
- 520 9_
- $a Autoinflammatory diseases (AIDs) represent a rare and heterogeneous group of disorders characterized by recurrent episodes of inflammation and a broad range of clinical manifestations. The most common symptoms involve recurrent fevers, musculoskeletal symptoms, and serositis; however, AIDs can also lead to life-threatening complications, such as macrophage activation syndrome (MAS) and systemic AA amyloidosis. Typical monogenic periodic fever syndromes include cryopyrin-associated periodic fever syndrome (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency/hyper IgD syndrome (MKD/HIDS), and familial Mediterranean fever (FMF). However, a number of other clinical entities, such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease (AOSD), Kawasaki disease (KD) and idiopathic recurrent pericarditis (IRP), display similar phenotypical and immunological features to AIDs. All these diseases are pathophysiologicaly characterized by dysregulation of the innate immune system and the central pathogenic role is attributed to the IL-1 cytokine family (IL-1α, IL-1β, IL-1Ra, IL-18, IL-36Ra, IL-36α, IL-37, IL-36β, IL-36g, IL-38, and IL-33). Therefore, reasonable therapeutic approaches aim to inhibit these cytokines and their pathways. To date, several anti-IL-1 therapies have evolved. Each drug differs in structure, mechanism of action, efficacy for the treatment of selected diseases, and side effects. Most of the available data regarding the efficacy and safety of IL-1 inhibitors are related to anakinra, canakinumab, and rilonacept. Other promising therapeutics, such as gevokizumab, tadekinig alfa, and tranilast are currently undergoing clinical trials. In this review, we provide sophisticated and up-to-date insight into the therapeutic uses of different IL-1 inhibitors in monogenic periodic fever syndromes.
- 650 _2
- $a antiflogistika $x terapeutické užití $7 D000893
- 650 _2
- $a dědičné zánětlivé autoimunitní nemoci $x farmakoterapie $x imunologie $7 D056660
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interleukin-1 $x antagonisté a inhibitory $7 D007375
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Strizova, Zuzana $u Department of Immunology, Second Faculty of Medicine Charles University and University Hospital Motol, Prague, Czechia
- 700 1_
- $a Milota, Tomas $u Department of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia $u Department of Immunology, Second Faculty of Medicine Charles University and University Hospital Motol, Prague, Czechia
- 700 1_
- $a Striz, Ilja $u Department of Clinical Immunology and Allergology, Institute for Clinical and Experimental Medicine, Prague, Czechia
- 700 1_
- $a Sediva, Anna $u Department of Immunology, Second Faculty of Medicine Charles University and University Hospital Motol, Prague, Czechia
- 700 1_
- $a Cebecauerová, Dita $u Department of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia $7 xx0272168
- 700 1_
- $a Horvath, Rudolf $u Department of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia $u Department of Immunology, Second Faculty of Medicine Charles University and University Hospital Motol, Prague, Czechia
- 773 0_
- $w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 11, č. - (2020), s. 619257
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33603750 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20220425111547 $b ABA008
- 999 __
- $a ok $b bmc $g 1690204 $s 1139771
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 11 $c - $d 619257 $e 20210201 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
- LZP __
- $a Pubmed-20210728